Pfizer
3/10
Risk level moved from Medium Risk to Low Risk. Score changed by 1 point as of 2026-05-10.
Pfizer has $64.6B in scheduled debt maturities. While near-term maturities are manageable at $3.0B, the total $64.6B maturity schedule represents a substantial long-term obligation. DebtCanary scores PFE at 3/10, suggesting manageable refinancing risk.
Maturity Schedule
| Period | Amount Due |
|---|---|
| Year 1 (0-12 months) | $3.0B |
| Year 2 (12-24 months) | N/A |
| Year 3 (24-36 months) | N/A |
| Year 4 (36-48 months) | N/A |
| Year 5 (48-60 months) | N/A |
| Beyond 5 Years | $61.6B |
| Total Scheduled Maturities | $64.6B |
Key Metrics
Score Components
| Component | Value |
|---|---|
| Near-Term Maturity Concentration | 4.6% |
| Interest Coverage Ratio | N/A |
| Debt-to-Equity Ratio | 0.72 |
| Cash Coverage of Near-Term Debt | 0.57x |
Recent SEC Filings
Material disclosures from Pfizer's most recent EDGAR filings. 8-K item labels indicate the type of event reported.
Related Companies
Data Source:
Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports).
Fiscal period end: 2026-03-29.
Filing date: 2026-05-05.
Data last fetched: 2026-05-10.
Maturity schedules reflect the company's most recently reported debt repayment obligations.
Data quality: Partial.
View SEC EDGAR filings for Pfizer →